Overview

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH). The primary objective of this study is to learn how effective it is to switch to BIC/LEN FDC tablets versus continuing on B/F/TAF FDC tablets in virologically suppressed PWH.

Phase:

PHASE3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

bictegravir
bictegravir, emtricitabine, tenofovir alafenamide, drug combination
lenacapavir